IGLV1-47: A Potential Drug Target and Biomarker (G28822)

Target Name: IGLV1-47

NCBI ID: G28822

IGLV1-47

Other Name(s): IGLV147 | V1-17 | immunoglobulin lambda variable 1-47 | Immunoglobulin lambda variable 1-47

IGLV1-47: A Potential Drug Target and Biomarker

IGLV1-47 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its function is not well understood, but it is known to play a role in the regulation of inflammation and immune responses. In recent years, researchers have been interested in using IGLV1-47 as a drug target or biomarker for various diseases, including diabetes, cancer, and neurodegenerative disorders.

Drug Target Potential

IGLV1-47 has been identified as a potential drug target due to its unique structure and its expression in different tissues. IGLV1-47 is a glycoprotein that consists of a transmembrane domain and an extracellular domain. The transmembrane domain is responsible for the protein's unique structure and functions as a receptor. The extracellular domain is involved in the protein's interactions with other molecules in the body.

Research has shown that IGLV1-47 is involved in the regulation of various immune responses, including inflammation and cellular responses. IGLV1-47 has been shown to play a role in the regulation of T cell responses, which are a crucial part of the immune system. IGLV1-47 has also been shown to be involved in the regulation of inflammation, which is a critical part of the immune response.

Biomarker Potential

IGLV1-47 has also been identified as a potential biomarker for various diseases. Its expression has been shown to be elevated in the brains of individuals with Alzheimer's disease, which is a neurodegenerative disorder that is characterized by the progressive loss of brain cells. IGLV1-47 has also been shown to be elevated in the blood of individuals with type 2 diabetes, which is a common form of diabetes that is characterized by high levels of blood sugar.

In addition to its potential as a drug target and biomarker, IGLV1-47 has also been shown to be involved in the regulation of various physiological processes in the body. For example, IGLV1-47 has been shown to play a role in the regulation of blood pressure, which is an important factor in maintaining overall cardiovascular health.

Conclusion

IGLV1-47 is a protein that has been shown to play a critical role in the regulation of various immune and physiological processes in the body. Its unique structure and its expression in different tissues make it an attractive potential drug target and biomarker. Further research is needed to fully understand the function of IGLV1-47 and its potential as a drug.

Protein Name: Immunoglobulin Lambda Variable 1-47

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGLV1-47 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV1-47 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets